Skip to main content
Top
Published in: Cancer Causes & Control 3/2013

01-03-2013 | Original paper

How can we make cancer survival statistics more useful for patients and clinicians: An illustration using localized prostate cancer in Sweden

Authors: Sandra Eloranta, Jan Adolfsson, Paul C. Lambert, Pär Stattin, Olof Akre, Therese M-L. Andersson, Paul W. Dickman

Published in: Cancer Causes & Control | Issue 3/2013

Login to get access

Abstract

Purpose

Studies of cancer patient survival typically report relative survival or cause-specific survival using data from patients diagnosed many years in the past. From a risk-communication perspective, such measures are suboptimal for several reasons; their interpretation is not transparent for non-specialists, competing causes of death are ignored and the estimates are unsuitable to predict the outcome of newly diagnosed patients. In this paper, we discuss the relative merits of recently developed alternatives to traditionally reported measures of cancer patient survival.

Methods

In a relative survival framework, using a period approach, we estimated probabilities of death in the presence of competing risks. To illustrate the methods, we present estimates of survival among 23,353 initially untreated, or hormonally treated men with intermediate- or high-risk localized prostate cancer using Swedish population-based data.

Results

Among all groups of newly diagnosed patients, the probability of dying from prostate cancer, accounting for competing risks, was lower compared to the corresponding estimates where competing risks were ignored. Accounting for competing deaths was particularly important for patients aged more than 70 years at diagnosis in order to avoid overestimating the risk of dying from prostate cancer.

Conclusions

We argue that period estimates of survival, accounting for competing risks, provide the tools to communicate the actual risk that cancer patients, diagnosed today, face to die from their disease. Such measures should offer a more useful basis for risk communication between patients and clinicians and we advocate their use as means to answer prognostic questions.
Literature
1.
go back to reference Dickman PW, Adami HO (2006) Interpreting trends in cancer patient survival. J Intern Med 260:103–117PubMedCrossRef Dickman PW, Adami HO (2006) Interpreting trends in cancer patient survival. J Intern Med 260:103–117PubMedCrossRef
2.
3.
go back to reference Dignam JJ, Kocherginsky MN (2008) Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 26:4027–4034PubMedCrossRef Dignam JJ, Kocherginsky MN (2008) Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 26:4027–4034PubMedCrossRef
4.
go back to reference Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26:2389–2430PubMedCrossRef Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26:2389–2430PubMedCrossRef
5.
go back to reference Gail MH (2008) Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies. Lifetime Data Anal 14:18–36PubMedCrossRef Gail MH (2008) Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies. Lifetime Data Anal 14:18–36PubMedCrossRef
6.
go back to reference Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, Bill-Axelsson BO, Damber JE, Hellström K, Hellström M, Holmberg E et al (2007) Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007(41):456–477CrossRef Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, Bill-Axelsson BO, Damber JE, Hellström K, Hellström M, Holmberg E et al (2007) Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007(41):456–477CrossRef
7.
go back to reference National Comprehensive Cancer Network (2010) Clinical practice guidelines in oncology, Prostate cancer, Version 1.2010 National Comprehensive Cancer Network (2010) Clinical practice guidelines in oncology, Prostate cancer, Version 1.2010
8.
go back to reference D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420–2425PubMedCrossRef D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420–2425PubMedCrossRef
9.
go back to reference Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516–1524PubMedCrossRef Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516–1524PubMedCrossRef
10.
go back to reference Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P, Adolfsson J (2010) Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28:3448–3456PubMedCrossRef Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P, Adolfsson J (2010) Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28:3448–3456PubMedCrossRef
11.
go back to reference Fang F, Fall K, Mittleman MA, Sparen P, Ye W, Adami HO, Valdimarsdóttir U (2012) Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med 366:1310–1318PubMedCrossRef Fang F, Fall K, Mittleman MA, Sparen P, Ye W, Adami HO, Valdimarsdóttir U (2012) Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med 366:1310–1318PubMedCrossRef
12.
go back to reference Brenner H, Gefeller O, Hakulinen T (2004) Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 40:326–335PubMedCrossRef Brenner H, Gefeller O, Hakulinen T (2004) Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer 40:326–335PubMedCrossRef
13.
go back to reference Brenner H, Hakulinen T (2002) Advanced detection of time trends in long-term cancer patient survival: experience from 50 years of cancer registration in Finland. Am J Epidemiol 156:566–577PubMedCrossRef Brenner H, Hakulinen T (2002) Advanced detection of time trends in long-term cancer patient survival: experience from 50 years of cancer registration in Finland. Am J Epidemiol 156:566–577PubMedCrossRef
14.
go back to reference Dickman PW, Sloggett A, Hills M, Hakulinen T (2004) Regression models for relative survival. Stat Med 23:51–64PubMedCrossRef Dickman PW, Sloggett A, Hills M, Hakulinen T (2004) Regression models for relative survival. Stat Med 23:51–64PubMedCrossRef
15.
go back to reference Perme MP, Henderson R, Stare J (2009) An approach to estimation in relative survival regression. Biostatistics 10:136–146PubMedCrossRef Perme MP, Henderson R, Stare J (2009) An approach to estimation in relative survival regression. Biostatistics 10:136–146PubMedCrossRef
16.
go back to reference Nelson CP, Lambert PC, Squire IB, Jones DR (2007) Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med 26:5486–5498PubMedCrossRef Nelson CP, Lambert PC, Squire IB, Jones DR (2007) Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med 26:5486–5498PubMedCrossRef
17.
go back to reference Lambert PC (2009) Further development of flexible parametric models for survival analysis. Stata J 9:265–290 Lambert PC (2009) Further development of flexible parametric models for survival analysis. Stata J 9:265–290
18.
19.
go back to reference Lambert PC, Dickman PW, Nelson CP, Royston P (2010) Estimating the crude probability of death due to cancer and other causes using relative survival models. Stat Med 29:885–895PubMedCrossRef Lambert PC, Dickman PW, Nelson CP, Royston P (2010) Estimating the crude probability of death due to cancer and other causes using relative survival models. Stat Med 29:885–895PubMedCrossRef
20.
go back to reference Brenner H, Arndt V (2005) Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 23:441–447PubMedCrossRef Brenner H, Arndt V (2005) Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 23:441–447PubMedCrossRef
21.
go back to reference Holmberg L, Robinson D, Sandin F, Bray F, Linklater KM, Klint A, Lambert PC, Adolfsson J, Hamdy FC, Catto J, Møller H (2012) A comparison of prostate cancer survival in England, Norway and Sweden: a population-based study. Cancer Epidemiol 36:e7–e12PubMedCrossRef Holmberg L, Robinson D, Sandin F, Bray F, Linklater KM, Klint A, Lambert PC, Adolfsson J, Hamdy FC, Catto J, Møller H (2012) A comparison of prostate cancer survival in England, Norway and Sweden: a population-based study. Cancer Epidemiol 36:e7–e12PubMedCrossRef
22.
go back to reference Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J (2010) Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 102:950–958PubMedCrossRef Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J (2010) Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 102:950–958PubMedCrossRef
23.
go back to reference Hinchliffe SR, Abrams KR, Lambert PC (2012) The impact of under and over-recording of cancer on death certificates in a competing risks analysis: a simulation study. Cancer Epidemiol (Epub ahead of print). doi:10.1016/j.canep.2012.08.012 Hinchliffe SR, Abrams KR, Lambert PC (2012) The impact of under and over-recording of cancer on death certificates in a competing risks analysis: a simulation study. Cancer Epidemiol (Epub ahead of print). doi:10.​1016/​j.​canep.​2012.​08.​012
24.
go back to reference Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102:1584–1598PubMedCrossRef Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA (2010) Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 102:1584–1598PubMedCrossRef
25.
go back to reference Finnish Cancer Registry-Institute for Statistical and Epidemiological Cancer Research (2009) Cancer in Finland 2006 and 2007. Helsinki 2009. Publication No. 76 Finnish Cancer Registry-Institute for Statistical and Epidemiological Cancer Research (2009) Cancer in Finland 2006 and 2007. Helsinki 2009. Publication No. 76
26.
go back to reference Koller MT, Raatz H, Steyerberg EW, Wolbers M (2011) Competing risks and the clinical community: irrelevance or ignorance? Stat Med 31:1089–1097PubMedCrossRef Koller MT, Raatz H, Steyerberg EW, Wolbers M (2011) Competing risks and the clinical community: irrelevance or ignorance? Stat Med 31:1089–1097PubMedCrossRef
27.
go back to reference Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF et al (2012) The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer 118:5652–5662PubMedCrossRef Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF et al (2012) The Cancer Survival Query System: making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer 118:5652–5662PubMedCrossRef
28.
go back to reference Brenner H, Hakulinen T (2003) On crude and age-adjusted relative survival rates. J Clin Epidemiol 56:1185–1191PubMedCrossRef Brenner H, Hakulinen T (2003) On crude and age-adjusted relative survival rates. J Clin Epidemiol 56:1185–1191PubMedCrossRef
29.
go back to reference Pokhrel A, Hakulinen T (2008) How to interpret the relative survival ratios of cancer patients. Eur J Cancer 44:2661–2667PubMedCrossRef Pokhrel A, Hakulinen T (2008) How to interpret the relative survival ratios of cancer patients. Eur J Cancer 44:2661–2667PubMedCrossRef
30.
go back to reference Fagerlin A, Zikmund-Fisher BJ, Ubel PA (2011) Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst 103:1436–1443PubMedCrossRef Fagerlin A, Zikmund-Fisher BJ, Ubel PA (2011) Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst 103:1436–1443PubMedCrossRef
31.
go back to reference Lipkus IM (2007) Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Mak 27:696–713CrossRef Lipkus IM (2007) Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Mak 27:696–713CrossRef
32.
go back to reference Lambert PC, Royston P (2009) Further development of flexible parametric models for survival analysis. Stata J 9:265–290 Lambert PC, Royston P (2009) Further development of flexible parametric models for survival analysis. Stata J 9:265–290
Metadata
Title
How can we make cancer survival statistics more useful for patients and clinicians: An illustration using localized prostate cancer in Sweden
Authors
Sandra Eloranta
Jan Adolfsson
Paul C. Lambert
Pär Stattin
Olof Akre
Therese M-L. Andersson
Paul W. Dickman
Publication date
01-03-2013
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 3/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0141-5

Other articles of this Issue 3/2013

Cancer Causes & Control 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine